European Hematology Association Congress | Conference

Shaji Kumar, MD, Details Toxicities With Daratumumab Plus Lenalidomide/Dexamethasone in Frontline MM
July 14, 2021

At EHA 2021, Shaji Kumar, MD, reviews the toxicity profile of daratumumab plus lenalidomide and dexamethasone for patients with transplant-ineligible multiple myeloma in the first-line setting.

Shaji Kumar, MD, Reviews PFS With Daratumumab-Containing Therapy in Frontline Myeloma
July 06, 2021

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of a daratumumab combination in patients with multiple myeloma.

Shaji Kumar, MD, Discusses 5-Year Overall Survival Data for MM Daratumumab Combo in the MAIA Study
June 29, 2021

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of daratumumab plus lenalidomide/dexamethasone in patients with newly diagnosed multiple myeloma.